top of page

Our Platform

Our diagnostic test platform is based on the classic hemagglutination (red blood cell clumping) test. Hemagglutination is a well established and highly sensitive diagnostic test, which is commonly used for blood typing, but can also be used for antibody testing, in particular in point-of-care settings. One drawback of current hemagglutination tests is the subjective readout by the human eye, which can lead to incorrect test interpretation. Moreover, current tests lack the ability to quantify test results.

To overcome these limitations, we developed an AI-based approach, which uses cell phone images of the hemagglutination reaction for objective test interpretation. Moreover, we included internal standards into each test card, which extends capabilities to quantitative test interpretation right at the point-of-care.

The Technology

Screen Shot 2023-02-11 at 3.10.33 PM.png

The method is based on a recombinant, bi-functional protein containing a high-affinity binding site for red blood cells and a protein that serves as a target (antigen) for the antibodies to be detected. Upon mixing with venous or finger-stick blood, the recombinant protein will bind to red blood cells (RBC). If antibodies (e.g. against SARS-CoV2) are present, they will bind to the bi-functional protein, resulting in crosslinking and visually apparent hemagglutination (clumping) of the RBC. In the absence of antibodies, the RBC will not agglutinate.

The Agglutination Reaction

Screen Shot 2023-02-11 at 3.14.26 PM.png reagent added to whole blood

Screen Shot 2023-02-11 at 3.14.34 PM.png reagent binds to red blood cells

Screen Shot 2023-02-11 at 3.14.41 PM.png

Antibodies present in whole blood bind to antigen present in the reagents and cause agglutination (clumping) of red blood cells


Our APP for AI-based Diagnostic Testing

While a positive (agglutination) or negative (no agglutination) result can be determined from the card alone the app is required for AI-based analysis and precise quantification of the test result. The user-friendly app can be downloaded from the app store. The app provides data entry, scanning, automatic data upload, and result return. The app also provides instructions, video tutorials and frequently asked questions to assist the user in running a successful test.

Test Procedure

The Advantage

The Nanospot Advantage

Learn More About Our Products

Our flagship product is the Sars-CoV-2 antibody test. The testing platform can easily expanded to other serology tests and beyond. Several additional tests from blood grouping to infectious diseases are currently in the pipeline and are expected to be released soon.

Screen Shot 2023-02-11 at 2.07_edited.png

Sars-CoV-2 antibody test

The rapid SARS-CoV-2 Total Antibody test is a semi-quantitative Covid-19 antibody test that provides fast, accurate and semi-quantitative antibody level results.

Screen Shot 2023-02-11 at 2.07_edited.png

Blood Grouping Test

The rapid ABO/RhDblood grouping kit allows safe, easy and fast determination of your blood type and Rh factor on site and at home. 

The SARS-CoV-2 Total Antibody Test has been CE Marked.


The SARS-CoV-2 Total Antibody Test has not been FDA cleared, approved, or authorized under an emergency use authorization.


The Website may depict certain of our future planned care offerings which are subject to completion of development and may require regulatory authorization, clearance, or approval before they can be commercialized.

bottom of page